Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen

Int J Antimicrob Agents. 2014 Dec;44(6):528-32. doi: 10.1016/j.ijantimicag.2014.07.026. Epub 2014 Sep 18.

Abstract

Serological, molecular and phylogenetic analyses of a recently imported case of Middle East respiratory syndrome coronavirus (MERS-CoV) in Greece are reported. Although MERS-CoV remained detectable in the respiratory tract secretions of the patient until the fourth week of illness, viraemia was last detected 2 days after initiation of triple combination therapy with pegylated interferon, ribavirin and lopinavir/ritonavir, administered from Day 13 of illness. Phylogenetic analysis of the virus showed close similarity with other human MERS-CoVs from the recent Jeddah outbreak in Saudi Arabia. Immunoglobulin G (IgG) titres peaked 3 weeks after the onset of illness, whilst IgM levels remained constantly elevated during the follow-up period (second to fifth week of illness). Serological testing confirmed by virus neutralisation assay detected an additional case that was a close contact of the patient.

Keywords: Antiviral treatment; Coronavirus; MERS; MERS-CoV; Phylogeny; Serology.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / virology
  • Drug Combinations
  • Drug Therapy, Combination
  • Greece
  • Humans
  • Lopinavir
  • Male
  • Middle East Respiratory Syndrome Coronavirus / drug effects*
  • Middle East Respiratory Syndrome Coronavirus / genetics
  • Middle East Respiratory Syndrome Coronavirus / immunology
  • Phylogeny
  • Respiratory Tract Infections / drug therapy*
  • Respiratory Tract Infections / virology
  • Ribavirin / therapeutic use*
  • Ritonavir
  • Viremia
  • Virus Shedding

Substances

  • Antiviral Agents
  • Drug Combinations
  • lopinavir-ritonavir drug combination
  • Lopinavir
  • Ribavirin
  • Ritonavir